GLP-1 drugs and healthy aging
Semaglutide, tirzepatide and related drugs are increasingly discussed as treatments for aging itself. This collection records what the published evidence actually shows, and how much of it applies to healthy normal-weight adults aged 55–75.
- Studies recorded
- 4750 enrolled the target group directly.
- Claims assessed
- 22Each claim is a single testable statement, with the evidence for and against it.
- Open questions
- 11What is not known, and what study would settle it.
- Trials watched
- 317Registered trials, checked for status and date changes.
- Snapshot
- Oct 19, 2026
Counts are from the snapshot date above. Assessments marked unreviewed have not been checked by a person.
The question every entry answers
Does this study show benefit or harm in people without obesity or diabetes? Most GLP-1 research enrolled people with one or both. An effect in those groups is recorded as evidence about those groups, and is never counted as evidence for healthy normal-weight adults aged 55–75.
Much of the benefit seen in trials may also come from weight loss itself rather than from the drug. Every study records whether that possibility was tested.
Claims, and where the evidence stands
- GLP-1 receptor agonist therapy provides a net clinical benefit to healthy normal-weight adults aged 55-75.Insufficient evidence · Evidence stable
- GLP-1 receptor agonist treatment reduces systemic inflammatory markers beyond what can be explained by treatment-associated weight loss.Plausible unproven · Evidence weakening
- The cardiovascular benefit of GLP-1 receptor agonists is not explained by weight loss.Probable · Evidence stable
- GLP-1 receptor agonists reduce cardiovascular events in people without obesity or established cardiovascular disease.Insufficient evidence · Evidence stable
- GLP-1 receptor agonist treatment reduces the risk of developing dementia.Plausible unproven · Evidence unclear
- GLP-1 receptor agonists slow clinical progression of Alzheimer's disease.Not supported · Evidence weakening
Recent changes in the evidence
- Possible safety signal (Anesthesia / perioperative): Impact of GLP-1 Agonists on Post-Operative Outcomes in Aesthetic & Body Contouring Surgery: A Systematic Review & Meta-AnalysisNew safety signal · Oct 18, 2026 · Major
Impact of GLP-1 Agonists on Post-Operative Outcomes in Aesthetic & Body Contouring Surgery: A Systematic Review & Meta-Analysis (Plastic and reconstructive surgery, 2026; PMID 42879169) reports a harm-direction finding. Assess design (Meta-analysis), absolute risk and replication before treating this as established.
- Human evidence including non-obese or healthy participants: Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart RegistryNon obese human evidence · Oct 11, 2026 · Major
Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart Registry (JACC. Advances, 2026; PMID 42858539) reports on non-obese or healthy participants. Evidence in people outside the obesity/diabetes populations directly addresses the core question of this observatory and should be reviewed first.
- Possible safety signal (Adverse effects / safety, Gastrointestinal): Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trialNew safety signal · Oct 4, 2026 · Major
Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial (Lancet (London, England), 2026; PMID 42815506) reports a harm-direction finding. Assess design (Randomized controlled trial), absolute risk and replication before treating this as established.
- Possible safety signal (Adverse effects / safety, Gastrointestinal): Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trialNew safety signal · Oct 4, 2026 · Major
Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial (Nature medicine, 2026; PMID 42811187) reports a harm-direction finding. Assess design (Randomized controlled trial), absolute risk and replication before treating this as established.
- Null randomized result after encouraging observational data in 'Inflammation': Effects of semaglutide on subclinical cardiovascular health in people with HIVNegative rct after observational · Sep 20, 2026 · Major
Effects of semaglutide on subclinical cardiovascular health in people with HIV (AIDS (London, England), 2026; PMID 42752515) reports no benefit, whereas 3 earlier observational record(s) in this domain suggested benefit. This pattern often indicates confounding by indication or healthy-user bias in the observational data.
- Null randomized result after encouraging observational data in 'Cardiovascular': Effects of semaglutide on subclinical cardiovascular health in people with HIVNegative rct after observational · Sep 20, 2026 · Major
Effects of semaglutide on subclinical cardiovascular health in people with HIV (AIDS (London, England), 2026; PMID 42752515) reports no benefit, whereas 9 earlier observational record(s) in this domain suggested benefit. This pattern often indicates confounding by indication or healthy-user bias in the observational data.
Trials enrolling people without obesity
- Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie DietNCT04122716 · Unknown · Phase 4 · Primary completion 2019-11
- Effects of Liraglutide in Chronic Obstructive Pulmonary DiseaseNCT03466021 · Completed · Phase 4 · Primary completion 2020-05-31
- Dulaglutide and Insulin MicrosecretiON in Type 1 DiabetesNCT03668470 · Completed · Phase 2 · Primary completion 2021-02-03
- Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male VolunteersNCT03835013 · Completed · NA · Primary completion 2021-11-01
- Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial DiseaseNCT04146155 · Unknown · Phase 4 · Primary completion 2021-12-31
- Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia.NCT04969627 · Completed · Phase 4 · Primary completion 2022-01-04